Search


 
 
Blog : Displaying 987-990 of 1341


And the Band Played On

Posted by Osagie Obasogie on January 3rd, 2009


In this time of economic recession, many companies selling luxury goods are having a hard time making the case to consumers that their services are still worthy of premium prices. In the recreational genetics industry, a number of outfits have tried slashing prices or repackaging their products for the holidays to stir up demand. But the pet cloning company BioArts has tried to maintain interests in its service – which can run tens of thousands of dollars per cloned animal – through working the media.

First, there was the global auctioning of five dog cloning procedures. This was followed by the Willy Wonkish Golden Clone Giveaway whereby a ticket to have one’s dog cloned for free was given to the person with the best 500 word essay.

Now, BioArts is using the one-year birthday of the world’s first cloned pet dog as a way to promote its service. (Click here and here for coverage). Although cloning seems to capture the imagination and many people would do anything to keep Fido around forever, BioArts is certainly facing an uphill battle: many people simply can’t afford pets during these times, let alone pay upwards of $50,000 to replicate them.

Nevertheless, the dangers that pet cloning portends for our human future remain quite real. The New York Times’ coverage of BioArts captures the sentiment behind pet cloning that, if applied to human reproductive cloning, may lead us back down a very dark path:

When Mr. Hawthorne recalls Missy [the “original” dog from which clones were made], he tends to wax eugenic. “She was an amazing dog: superior intellect, incredibly beautiful, obedient, a phenomenal temperament,” he said. “I especially loved her majestic plume of a tail.” And in the clones, as he put it matter-of-factly, “all those qualities are represented.”




This Week in the News: New Year's Edition

Posted by Jesse Reynolds on January 1st, 2009


Here are a few stories that we've not covered here at Biopolitical Times. You can stay up-to-date on the news with CGS's news compilation, available as a web page, RSS feed, or weekly email.

The Associated Press reports on the rise of do-it-yourself biotechnology in the garage.

Maura Dolan and Jason Felch authored another installment in the excellent series on the use of DNA in forensics in the Los Angeles Times.

Commercial surrogacy appears to be on the rise in Uganda.

The first study of long-term risks of providing eggs for assisted reproduction was published in Fertility and Sterility.

A 2003 Missouri law that provides public funds for life sciences research may need to be revised due to the 2006 passage of a state constitutional amendment to protect stem cell research. Cloning-based stem cell research was explicitly ineligible for funds under the original law. But the constitutional amendment prohibits any such discrimination by the state, even though cloning-based stem cell researchis not occurring in Missouri.

This is more than a week old, but it warrants a mention here: The Catholic Vatican issued its first lenthy statement on assisted reproduction since 1987. 





St. Petersburg Times Covers Clinical Trial Outsourcing to India

Posted by Osagie K. Obasogie on December 31st, 2008


When we think of Pulitzer prize winning newspaper series, we often think of the New York Times or the Washington Post. But a new special report in the St. Petersburg Times on clinical trials in the developing world should give the big boys a run for their money next year. Staff writer Kris Hundley traveled to India on a journalism fellowship and documented the extraordinary risks taken by some of the world’s poorest patients to test medicines destined for people halfway around the world.  

Recalling the harrowing personal experiences, harsh conditions, and institutional practices behind these endeavors, Hundley’s writings are as much of an indictment of the industry as the 2005 Bloomberg Markets article Big Pharma’s Shameful Secret that looked at the domestic side of things. Taken together, they raise a broader question: how much longer can the FDA allow new drugs’ safety and efficacy to be determined in this manner? 






Gene Doping Conference Makes Headlines

Posted by Marcy Darnovsky on December 24th, 2008


Illustration by Duane Hoffmann

The prospect of gene doping by athletes is widely condemned, and has been banned by the World Anti-Doping Agency (WADA) and the International Olympic Committee. But a few "pro-doping" advocates regularly make the news [1, 2], as they did at a conference last week called "The Coming Age of the Uber-Athlete: What's So Bad about Gene Enhancement and Doping?"

The event was sponsored by the American Enterprise Institute, the conservative think tank that's been described as "one of the leading architects of the second Bush administration's public policy." AEI Visiting Fellow Jon Entine opened the conference and moderated one of its panels. He is the author of the provocative book Taboo: Why Black Athletes Dominate Sports and Why We're Afraid to Talk About It, and has speculated about "Jewish intelligence genes."

Among the speakers opposing gene doping were representatives of the US Anti-Doping Agency and the US Olympic Committee, and an Olympic champion hurdler who asked,

"How do you feel if it's your son or your daughter who wants to be an Olympian? Would you let your kid or your grandchild take what they have to take? Or do what they have to do?"

Theodore Friedmann, a University of California San Diego human gene therapy researcher who has been writing about the risks of gene doping in sports for several years, said that nobody knows whether athletes are currently attempting gene doping.

As to its risks, Friedmann said bluntly, "People are injured. People die.[Gene transfer] should be reserved for treatment of people with serious diseases."

Previously on Biopolitical Times:





Displaying 987-990 of 1341  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 

 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications | about us | donate | newsletter | press room | privacy policy

CGS • 1120 University Ave, Suite 100, Berkeley, CA 94702 USA • • (p) 1.510.625.0819 • (F) 1.510.665.8760